Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Takeda, HemoShear Expand NASH Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Takeda, HemoShear Expand NASH Pact

Several drug targets shown to inhibit biological processes associated with inflammation and fibrosis that can lead to nonalcoholic steatohepatitis

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

HemoShear Therapeutics, LLC has extended its partnership with Takeda Pharmaceutical Co. to discover and develop additional novel therapeutics for liver diseases, including nonalcoholic steatohepatitis (NASH).

Under the original agreement, HemoShear received upfront payments and R&D funding, and Takeda received exclusive access to HemoShear’s disease modeling platform to discover and develop best-in-class therapeutics for specific liver diseases. HemoShear is eligible to receive milestone payments of potentially $470 million and royalties.

The partnership has generated several early drug discovery targets shown to inhibit biological processes associated with inflammation and fibrosis that can lead to nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer.  

“We are excited that Takeda recognizes our unique ability to identify novel therapeutic approaches for liver fibrosis and NASH,” said Jim Powers, HemoShear’s chief executive officer. “We have an incredibly strong and productive relationship with Takeda and are happy to see our science drive their decision to expand our partnership.”

“Our partnership with HemoShear has already borne fruit and we are enthusiastic about expanding the relationship,” said Gareth Hicks, Ph.D., head of GI Drug Discovery at Takeda. “We are planning to advance novel drug targets identified and validated by HemoShear into our discovery pipeline and look forward to bringing new therapies to the clinic.”

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics